Business
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":" ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the H.C. Wainwright 26th Annual Global Investment Conference in New York City, September 9-11, 2024.\n\n\nAurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, September 10, at 10:30 AM EST. This session will not include a webcast.\n\n\nAbout Aurinia\nAurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, and its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240828651786/en/\n\nMedia & Investor Inquiries:\nAndrea Christopher,\nCorporate Communications & Investor Relations, Aurinia\[email protected]\n\n\nGeneral Investor Inquiries:\[email protected]\n\n\nSource: Aurinia Pharmaceuticals Inc.","length":2608,"tagName":"div"}]